SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17).

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO ...

Aadi Bioscience, Inc. , an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the ...

A recent study has uncovered the pivotal role of the transcription factor SOX9 in the development of hypospadias, a common congenital condition that ...

The intrinsic factor of cell senescence, PCBP2, was identified by unlabeled quantitative proteomics, and its biological role in in vitro replication senescence of human bone marrow mesenchymal stromal ...

Through comparative transcriptome analysis, Professor Kai-Chien Yang's group identified the adherens junction protein N-Cadherin as a key regulator of CM proliferation and renewal. Its expression ...

followed by overnight incubation at 4°C with primary antibodies against GREM1 (1:1000, Affinity), E-cadherin (1:20000, Proteintech), N-cadherin (1:3000, Proteintech), Vimentin (1:50000, Proteintech), ...

Methods HBECs from non-smokers (n=5), smokers (n=12) and patients with COPD (n=15) were collected to measure the mesenchymal markers α-smooth muscle actin, vimentin and collagen type I and the ...